$15.62
1.63% yesterday
Nasdaq, May 28, 09:47 pm CET
ISIN
US04280A1007
Symbol
ARWR

Arrowhead Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Arrowhead Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
69%
Hold
31%

Arrowhead Pharmaceuticals, Inc. Price Target

Target Price $42.31
Price $15.56
Potential
Number of Estimates 13
13 Analysts have issued a price target Arrowhead Pharmaceuticals, Inc. 2026 . The average Arrowhead Pharmaceuticals, Inc. target price is $42.31. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 16 analysts: 11 Analysts recommend Arrowhead Pharmaceuticals, Inc. to buy, 5 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Arrowhead Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Arrowhead Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Sep '24 2025
Estimates
Revenue Million $ 3.55 719.54
98.53% 20,168.80%
EBITDA Margin -16,408.17% 13.74%
20,416.60% 100.08%
Net Margin -16,887.04% 7.33%
19,698.88% 100.04%

15 Analysts have issued a sales forecast Arrowhead Pharmaceuticals, Inc. 2025 . The average Arrowhead Pharmaceuticals, Inc. sales estimate is

$720m
Unlock
. This is
31.98% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.0b 85.00%
Unlock
, the lowest is
$545m 0.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $3.6m 98.53%
2025
$720m 20,168.80%
Unlock
2026
$282m 60.85%
Unlock
2027
$297m 5.49%
Unlock
2028
$424m 42.62%
Unlock
2029
$735m 73.49%
Unlock

6 Analysts have issued an Arrowhead Pharmaceuticals, Inc. EBITDA forecast 2025. The average Arrowhead Pharmaceuticals, Inc. EBITDA estimate is

$98.9m
Unlock
. This is
201.51% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$376m 485.53%
Unlock
, the lowest is
$-33.6m 65.53%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-582m 202.59%
2025
$98.9m 116.98%
Unlock
2026
$-393m 497.23%
Unlock
2027
$-553m 40.70%
Unlock
2028
$-456m 17.50%
Unlock
2029
$-171m 62.59%
Unlock

EBITDA Margin

2024 -16,408.17% 20,416.60%
2025
13.74% 100.08%
Unlock
2026
-139.46% 1,114.99%
Unlock
2027
-186.02% 33.39%
Unlock
2028
-107.60% 42.16%
Unlock
2029
-23.20% 78.44%
Unlock

6 Arrowhead Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Arrowhead Pharmaceuticals, Inc. net profit estimate is

$52.7m
Unlock
. This is
136.63% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$332m 330.83%
Unlock
, the lowest is
$-295m 105.22%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-599m 192.01%
2025
$52.7m 108.80%
Unlock
2026
$-438m 931.10%
Unlock
2027
$-439m 0.18%
Unlock
2028
$-474m 7.89%
Unlock
2029
$-303m 36.11%
Unlock

Net Margin

2024 -16,887.04% 19,698.88%
2025
7.33% 100.04%
Unlock
2026
-155.58% 2,222.51%
Unlock
2027
-147.75% 5.03%
Unlock
2028
-111.77% 24.35%
Unlock
2029
-41.16% 63.17%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Sep '24 2025
Estimates
Earnings Per Share $ -5.00 0.38
160.42% 107.60%
P/E 40.24
EV/Sales 1.81

6 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast for earnings per share. The average Arrowhead Pharmaceuticals, Inc. EPS is

$0.38
Unlock
. This is
135.51% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$2.41 325.23%
Unlock
, the lowest is
$-2.14 100.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.00 160.42%
2025
$0.38 107.60%
Unlock
2026
$-3.17 934.21%
Unlock
2027
$-3.18 0.32%
Unlock
2028
$-3.43 7.86%
Unlock
2029
$-2.19 36.15%
Unlock

P/E ratio

Current -14.36 119.97%
2025
40.24 380.14%
Unlock
2026
-4.84 112.03%
Unlock
2027
-4.83 0.21%
Unlock
2028
-4.48 7.25%
Unlock
2029
-7.01 56.47%
Unlock

Based on analysts' sales estimates for 2025, the Arrowhead Pharmaceuticals, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.39 96.70%
2025
1.81 24.33%
Unlock
2026
4.62 155.44%
Unlock
2027
4.38 5.20%
Unlock
2028
3.07 29.89%
Unlock
2029
1.77 42.36%
Unlock

P/S ratio

Current 3.89 95.53%
2025
2.95 24.23%
Unlock
2026
7.54 155.44%
Unlock
2027
7.14 5.20%
Unlock
2028
5.01 29.88%
Unlock
2029
2.89 42.36%
Unlock

Current Arrowhead Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked May 20 2025
Citigroup
Locked
Locked
Locked May 13 2025
Chardan Capital
Locked
Locked
Locked May 13 2025
B. Riley Securities
Locked
Locked
Locked Feb 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 12 2025
RBC Capital
Locked
Locked
Locked Feb 11 2025
Chardan Capital
Locked
Locked
Locked Feb 11 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
May 20 2025
Locked
Citigroup:
Locked
Locked
May 13 2025
Locked
Chardan Capital:
Locked
Locked
May 13 2025
Locked
B. Riley Securities:
Locked
Locked
Feb 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 12 2025
Locked
RBC Capital:
Locked
Locked
Feb 11 2025
Locked
Chardan Capital:
Locked
Locked
Feb 11 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today